Financial Performance - The company's revenue for Q1 2021 was CNY 2,268,544,975.62, representing a 52.97% increase compared to CNY 1,482,975,289.36 in the same period last year[3]. - Net profit attributable to shareholders was CNY 480,582,571.42, up 50.74% from CNY 318,806,306.55 year-on-year[3]. - The net profit after deducting non-recurring gains and losses was CNY 455,065,047.62, reflecting a 43.12% increase from CNY 317,949,508.13 in the previous year[3]. - Basic earnings per share increased by 33.07% to CNY 1.1268, compared to CNY 0.8468 in the previous year[3]. - Total operating revenue for Q1 2021 reached ¥1,403,053,485.12, a significant increase from ¥881,513,012.68 in the same period last year, representing a growth of approximately 59.1%[42]. - Net profit for Q1 2021 was ¥480,806,327.63, compared to ¥320,042,470.88 in Q1 2020, reflecting a year-over-year increase of about 50.2%[40]. - The company reported a total comprehensive income of ¥481,013,637.78 for Q1 2021, up from ¥320,333,858.36 in Q1 2020, which is an increase of approximately 50.2%[41]. Cash Flow and Liquidity - The net cash flow from operating activities decreased by 69.28% to CNY 187,866,670.61, down from CNY 611,546,751.39 in the same period last year[3]. - Cash received from investment increased by 389.32% to CNY 2.52 billion, attributed to the redemption of financial products[14]. - Cash inflow from operating activities totaled CNY 2,273,919,182.07, up from CNY 2,195,276,740.12 year-over-year[46]. - Cash received from sales of goods and services was CNY 2,204,595,850.27, compared to CNY 2,159,021,644.60 in the same period last year, indicating a growth of approximately 2%[45]. - The company reported a cash and cash equivalents balance of CNY 4,500,657,547.02 at the end of the quarter, up from CNY 879,822,844.73 at the end of the previous year[47]. - The company's cash and cash equivalents increased to RMB 4,513.22 million from RMB 4,162.54 million as of December 31, 2020, reflecting a growth of approximately 8.4%[31]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 13,550,059,545.19, a 4.21% increase from CNY 13,002,251,764.44 at the end of the previous year[3]. - The total liabilities increased to CNY 1,519,906,147.29 from CNY 2,037,718,375.39 year-over-year, indicating a reduction in overall debt levels[37]. - The total assets of the company reached RMB 13,550.06 million, compared to RMB 13,002.25 million at the end of 2020, marking an increase of about 4.2%[32]. - The total liabilities increased from CNY 2,533,861,673.00 to CNY 3,098,196,048.76, reflecting an increase of CNY 564,334,375.76[53]. - The company's total equity attributable to shareholders decreased by CNY 60,128,638.03, from CNY 10,453,934,045.43 to CNY 10,393,805,407.40[53]. Sales and Revenue Breakdown - Medical consumables sales amounted to CNY 1.38 billion, up 67.16% year-on-year, with overseas sales increasing by 404.87% to CNY 596 million[15]. - Health lifestyle consumer products generated sales of CNY 818 million, a 40.38% increase year-on-year, with full cotton products sales reaching CNY 807 million, up 41.39%[15]. - Medical supplies sales reached CNY 1,376,019,757.79 in Q1 2021, a significant increase of 67.15% compared to the same period last year[16]. - The top five customers contributed CNY 461,075,659.08, accounting for 20.32% of total revenue in Q1 2021[20]. - The company confirmed sales revenue of USD 11.7 million from a major contract, with a collection rate of 100%[17]. Investments and Expenditures - Research and development expenses rose by 125.87% to CNY 99.19 million, reflecting increased investment in R&D[13]. - The company has invested 14,923.09 million CNY in the current quarter, with a cumulative investment of 105,104.94 million CNY[24]. - The high-end dressing production line project has a total investment commitment of 21,685.86 million CNY, with 12.25% of the project completed[24]. - The marketing network construction project has a total investment commitment of 70,456.87 million CNY, with 19.80% of the project completed[24]. - The company’s investment in fixed assets and intangible assets amounted to CNY 336,705,004.90, compared to CNY 207,344,502.42 in the previous year[46]. Operational Efficiency - The weighted average return on equity was 4.51%, down 5.09% from 9.60% in the previous year[3]. - The company reported a decrease in employee compensation payable to CNY 127,608,466.45 from CNY 169,957,077.81, indicating improved operational efficiency[33]. - The company executed its annual business plan without significant adjustments during the reporting period[21]. - There were no significant changes in the company’s core technology team or major risks affecting operations during the reporting period[18]. Compliance and Governance - The company has not reported any non-compliance with external guarantees during the reporting period[27]. - There were no non-operational fund occupations by controlling shareholders or related parties during the reporting period[27]. - The first quarter report was not audited, indicating preliminary financial data[56].

COVID-19 Response - In 2020, the company provided nearly 4 billion masks and over 86 million pieces of protective clothing, isolation gowns, and surgical gowns in response to the COVID-19 pandemic[3]. - The company provided 1.089 billion masks and 114,000 protective suits to hospitals in Hubei during the initial outbreak of COVID-19, demonstrating its rapid response capabilities[59]. - The sales of medical prevention products, such as masks and protective clothing, significantly increased due to the COVID-19 pandemic, enhancing brand awareness and expanding sales channels[169]. Financial Performance - The company reported a revenue of RMB 1.2 billion for the fiscal year 2020, representing a year-over-year increase of 15%[9]. - The company's operating revenue for 2020 reached ¥12.53 billion, a 173.99% increase compared to ¥4.57 billion in 2019[16]. - Net profit attributable to shareholders was ¥3.81 billion, reflecting a 597.50% increase from ¥546 million in 2019[16]. - The net profit after deducting non-recurring gains and losses was ¥3.75 billion, up 680.69% from ¥480 million in 2019[16]. - The total assets at the end of 2020 amounted to ¥13.00 billion, representing a 186.93% increase from ¥4.53 billion at the end of 2019[16]. - The company achieved a basic earnings per share of ¥9.80, a 575.86% increase from ¥1.45 in 2019[16]. - The company's cash dividend is 18 RMB per 10 shares, totaling 767,686,154.40 CNY, which represents 20.15% of the net profit[181][185]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in sales from this region by 2022[10]. - A strategic acquisition of a local competitor is expected to enhance market share by 5% in the upcoming year[10]. - The company aims to enhance its e-commerce capabilities, with a target of increasing online sales by 40% in the next year[10]. - The company has established partnerships with multinational corporations and large pharmacy chains in the international market, which were previously difficult to penetrate[3]. - The company has expanded its product export countries from over 70 in 2019 to more than 110 in 2020, enhancing its global market presence[71]. Research and Development - Investment in R&D increased by 25%, focusing on innovative medical textile products and advanced manufacturing technologies[10]. - The company aims to prioritize the research and development of high-end wound care products and non-woven fabrics, striving for excellence in basic materials[5]. - The company has established two provincial-level R&D platforms focused on functional cotton products and wound repair materials[61]. - The company has obtained 117 utility model patents, 9 design patents, and 8 invention patents in 2020, enhancing its competitive edge[74]. - The company is in the process of developing 20 new medical consumables, with several projects in the R&D phase[123]. Product Development and Innovation - The company introduced three new product lines in 2020, contributing to 10% of total revenue[10]. - The company has developed high-end wet dressings for chronic wounds, including silicone foam dressings and hydrocolloid dressings, expanding its product offerings in the medical consumables sector[63]. - The company has launched innovative health consumer products, including cotton soft towels and sanitary napkins, which utilize biodegradable cotton and reduce chemical irritation, gaining significant consumer acceptance[64]. - The company has successfully developed and launched several products, including high-protection N95 masks and antibacterial masks, which are now on the market[123]. E-commerce and Sales Channels - The company’s e-commerce platform saw a rapid increase in member numbers, reflecting significant growth in consumer-facing products[3]. - The company has established partnerships with major e-commerce platforms, including Tmall and JD.com, to boost distribution channels[10]. - The company has expanded its sales channels to include major e-commerce platforms, effectively reaching a broad consumer base[67]. - Online sales generated revenue of approximately ¥2.34 billion, with a gross margin of 50.50%, reflecting a year-on-year increase of ¥664.50 million[105]. Quality Control and Compliance - The company has established a comprehensive quality management system and received ISO13485 certification, ensuring compliance with international standards[43]. - The company emphasizes high-quality control and technology development, using globally sourced premium cotton for its core products, ensuring product safety and environmental friendliness[26]. - The company has maintained a strong commitment to quality assurance and regulatory compliance across its product lines[134]. Employee and Incentive Plans - The company’s employee incentive plan includes granting restricted stock to no more than 1,036 employees, promoting shared growth between employees and the company[4]. - A total of 583,300 restricted stocks were granted to 1,036 eligible participants under the 2020 restricted stock incentive plan[198]. Challenges and Risks - The company faces risks of reduced orders for prevention products as global pandemic control improves and competition intensifies, leading to uncertainty in sustained sales growth[169]. - The company is actively pursuing opportunities for market expansion in both domestic and international markets[135]. - The company is implementing strategies to mitigate risks from raw material price fluctuations and exchange rate volatility, including forward contracts and price adjustment mechanisms[170][171].

Financial Performance - Total assets increased to CNY 12.57 billion, a growth of 177.42% compared to the previous year[5] - Net assets attributable to shareholders reached CNY 9.77 billion, up 209.15% year-over-year[5] - Operating revenue for the quarter was CNY 5.34 billion, representing a 427.36% increase compared to the same period last year[5] - Net profit attributable to shareholders was CNY 2.12 billion, a staggering increase of 1,112.76% year-over-year[6] - Net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 2.11 billion, up 1,149.91% compared to the previous year[6] - Net cash flow from operating activities reached CNY 1.49 billion, a significant increase of 4,691.43% year-over-year[6] - Basic earnings per share were CNY 5.63, reflecting a 1,123.91% increase compared to the same period last year[6] - Diluted earnings per share also stood at CNY 5.63, marking a 1,123.91% increase year-over-year[6] - The weighted average return on equity was 41.10%, an increase of 53.06% compared to the previous year[6] Shareholder Information - The largest shareholder, Steady Group Co., Ltd., holds 68.10% of the shares, totaling 290,438,848 shares[11] - The second-largest shareholder, Beijing Sequoia Xinyuan Equity Investment Center, holds 8.09% of the shares, totaling 34,500,000 shares[11] - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest three shareholders accounting for over 80% of the total shares[11] Government and Non-Operating Income - The total amount of non-operating income for the reporting period is 17,740,996.38 yuan, after deducting the impact of income tax and minority interests[9] - The company received government subsidies amounting to 43,589,033.78 yuan, which are closely related to its business operations[9] - The company reported a non-operating loss from the disposal of non-current assets amounting to -20,770,125.94 yuan[9] - The company does not have any non-recurring gains or losses that are classified as regular income for the reporting period[10] Financial Position and Assets - The company's cash and cash equivalents increased by 1,417.46% to approximately ¥7.30 billion as of September 30, 2020, primarily due to the successful IPO and significant sales growth[19] - Accounts receivable rose by 121.03% to approximately ¥920.24 million, attributed to increased sales[19] - The company's total liabilities increased significantly, with accounts payable rising by 31.21% to approximately ¥738.41 million, reflecting higher procurement costs[20] - The deferred income tax assets increased by 115.85% to approximately ¥149.71 million, due to the recognition of deductible temporary differences[19] - The company's retained earnings grew by 177.62% to approximately ¥4.77 billion, reflecting increased profits for the year[20] - The total current assets as of September 30, 2020, amounted to CNY 10,637,390,858.89, a significant increase from CNY 2,674,588,488.71 as of December 31, 2019, reflecting a growth of approximately 297%[44] - Cash and cash equivalents reached CNY 7,296,517,360.42, up from CNY 480,838,765.63 in the previous year, indicating a growth of about 1414%[44] Research and Development - R&D expenses surged to CNY 341.98 million, marking a 205.54% increase, primarily driven by increased investment in research and development[22] - Research and development expenses for the quarter were ¥173,137,833.52, significantly higher than ¥51,933,763.64 in the previous year, showing an increase of approximately 233%[61] Market and Product Development - The company has not disclosed any new product developments or technological advancements in this reporting period[12] - There are no indications of market expansion or mergers and acquisitions reported in the current financial results[12] - The company plans to invest approximately 1.5 billion in the construction of six major centers, including a non-woven fabric center and a medical sales marketing center[30] - The company is actively communicating with the local government regarding the recovery of remaining compensation related to a land dispute, with CNY 15 million already received[25] Cash Flow and Financing Activities - The net cash flow from operating activities for Q3 2020 was approximately CNY 3.24 billion, a significant increase compared to CNY 8.03 million in Q3 2019[87] - Cash received from the sale of goods and services amounted to CNY 10.61 billion, compared to CNY 3.46 billion in the same period last year[84] - The company reported a net cash outflow from investing activities of CNY 503.67 million, a decrease from CNY 437.06 million in the previous year[86] - Cash inflow from financing activities totaled CNY 3.74 billion, compared to CNY 406.29 million in the prior period[86] Tax and Compliance - The company did not report any non-standard audit opinions for the quarter[3] - The company has not disclosed any cash dividend policy execution during the reporting period[36] - There are no instances of irregular external guarantees reported during the period[38] - The company has not provided specific profit forecasts for the upcoming reporting period[32]